Uk Mhra Medical Device Registration Consultant

Scope and evidence must be confirmed before any paid tests or filings.

A UK MHRA medical device registration consultant should settle the regulatory decision before anyone buys testing, appoints an agent or enters products into DORS. The deliverable is a reasoned route decision and a ranked gap plan—not an assertion that registration itself permits market access.

MHRA registration is not MHRA approval, certification or endorsement. For Great Britain (England, Scotland and Wales), placing a device on the market generally requires both the applicable conformity route and MHRA registration before first supply. The distinct Northern Ireland rules must be checked separately.

Start with five facts that can change the legal answer

Ask the manufacturer for these five inputs. A product name or GMDN code alone cannot establish device status or risk class.

Intended purpose and claims: exact clinical claim, users, setting, labelling, website and software outputs; how the principal action is achieved.
Device architecture: invasiveness, duration, implant status, sterile or measuring features, software decision influence, accessory/combination status and—for IVDs—test purpose and users.
Territory and transaction: Great Britain, Northern Ireland or both; manufacturer location; sale, lease, gift, import or solely putting into service.
Existing route: UKCA or CE; EU MDR/IVDR versus earlier EU directives; certificates, declarations, issuing body, expiry and transition conditions.
Evidence and roles: technical file, clinical/performance evaluation, risk controls, QMS, PMS/vigilance arrangements, UK Responsible Person or EU/NI authorised representative.

Decision matrix: jurisdiction, marking and registration

These are screening outcomes, not a substitute for device-specific classification. CE transition eligibility must be proved, especially for older self-declared Class I and general IVD products. If the device is only put into service in GB without being placed on the GB market (for example certain in-house uses), MHRA says registration is encouraged but not mandatory. Do not apply this narrow distinction to ordinary sales, gifts or imports.

Case	Strategic route / constraint	Verify before commitment
GB: UKCA, ordinary Class I	Usually manufacturer self-declaration, then MHRA device registration before placing on market.	Confirm non-sterile, non-measuring Class I classification and complete conformity evidence.
GB: UKCA, IIa/IIb/III or sterile/measuring Class I	UK Approved Body involvement applies to the relevant conformity assessment scope; registration remains separate.	Classification rule, designated body scope, certificate/declaration and evidence readiness.
GB: UKCA, IVD	A general IVD can normally be self-declared under Part IV of the UK MDR 2002. Higher-risk IVD categories, including Annex II and self-testing devices, may require a UK Approved Body. MHRA registration remains separate.	Determine the GB IVD category under UK law, rather than using EU IVDR classes A–D as the UKCA decision rule.
GB: genuinely custom-made device	No UKCA mark or routine UK Approved Body assessment for a qualifying custom-made device; comply with the applicable UK MDR 2002 provisions and register with MHRA before GB market placement.	Confirm a patient-specific written prescription and the legal definition; verify the custom-made statement and retained technical records, including whether the statement must accompany this higher-class device.
GB: valid CE under EU MDD/AIMDD	Conditional GB recognition until the earlier of certificate expiry and 30 June 2028.	Actual continued certificate validity and legal transition eligibility; not every old Class I self-declaration qualifies.
GB: valid CE under EU IVDD	Conditional recognition until the earlier of certificate expiry and 30 June 2030.	Whether general IVD or other device qualifies under the stated transitional rules.
GB: valid CE under EU MDR/IVDR	Conditional recognition through 30 June 2030 under current rules.	Compliance, certificate/declaration scope and GB registration; no automatic MHRA approval.
NI: non-custom-made device	EU MDR/IVDR, CE route and EUDAMED device registration before placement from 28 May 2026; routine MHRA device registration is not required.	Authorised-representative duties where applicable; EU/NI operator registrations and any transition conditions.
NI: custom-made device	Different exception: register with MHRA within 28 days after making available in NI; not in EUDAMED.	Custom-made definition, EU MDR evidence and which party is to submit.

Legacy-IVD trap: the 30 June 2030 GB date is an outer ceiling, not automatic permission for an old self-declared IVDD product. For former general IVDs upclassified under EU IVDR, check Article 110 conditions and the class-specific validity limits: Class D to 31 December 2027, Class C to 31 December 2028 and Class B to 31 December 2029, where the transition applies. A device that does not qualify needs another lawful conformity route.

Proposals are not in-force rules: the 2026 consultation on indefinite GB recognition of CE marking does not itself extend any of these statutory deadlines. Recheck enacted law before committing to a launch schedule.

NI special routes: UKCA alone is not accepted in NI; where a UK notified body conducts the relevant NI assessment, CE + UKNI may be needed, and that combination cannot be used for the EU market. Qualifying Northern Ireland goods may have distinct indefinite access to GB; check qualifying status rather than applying the normal CE sunset mechanically.

IVDs used in UK performance-evaluation studies have separate MHRA pre-study registration guidance. Do not assume that the routine NI EUDAMED route for commercial products resolves the requirements for a study.

Evidence-reuse audit: what carries over, what does not

A CE dossier may shorten work, but never establishes UK eligibility by itself. Review each item against the selected law and the exact product variant. The classifications below are consulting judgments, not separate statutory categories.

Existing asset	Reuse test	Decision if deficient
Certificates / declaration	Identity, scope, issuing body, validity, applicable EU legislation and GB transition condition	STOP: no CE-reliance decision until proof is verified.
Claims, design and classification memo	Labels, website claims, software output and intended patient group match the assessed product	STOP: resolve borderline status or higher risk class before choosing assessment.
Clinical / performance and technical evidence	Evidence covers actual use, risk controls and variants; UKCA essential requirements mapped if UKCA chosen	REMEDIATE: determine whether targeted testing, evaluation or fresh assessment is needed.
QMS, PMS and incident workflow	Responsibilities and lifecycle records suit GB 2025 PMS requirements even for CE-marked devices	REMEDIATE before launch; do not treat CE marking as a PMS exemption.
Representation and device data	Manufacturer/UKRP mandates, importer details, GMDN level/category, model and applicable UDI fields align	PREPARE only after regulatory route is settled; prevent incorrect or duplicate registrations.

Rank gaps by the decision they block

Stop-work: unresolved device/medicine boundary, unsupported class, invalid CE basis, missing required third-party review, or missing representation. Remediation: product-specific evidence, quality/post-market procedures or labelling gaps. Administrative: verified device identifiers and DORS data. Do not let a clean application form hide a conformity problem.

Who owns the obligations—and the real fee driver

For GB, a manufacturer outside the UK must appoint a single UK Responsible Person (UKRP) for its devices; the UKRP handles MHRA registration on the manufacturer’s behalf. GB importers notify the manufacturer or UKRP, who provides importer details to MHRA. For NI, a manufacturer established outside the EU and Northern Ireland—including in Great Britain—must designate an EU- or NI-based authorised representative; this is a different role from a GB UKRP. A consultant is not automatically the UKRP or a conformity-assessment body.

Since 1 April 2026, MHRA uses an annual registration fee by manufacturer and GMDN Level 2 category (or Level 1 where Level 2 does not exist), not the former universal one-off registration charge. For 1 April 2026–31 March 2027 the unit is £300 per year per chargeable category, with pro-rata rules; future rates can change. Consultancy, UKRP and approved-body work are separate cost drivers. Check device-category mapping before forecasting fees.

For operational account setup, DORS data entry and changes, use the separate MHRA registration filing service guide.

For appointment terms, mandate and ongoing representative duties, use the UK Responsible Person service guide.

Three decision gates before filing or testing

Gate 1 — classification memo: record claims, jurisdiction, applicable instrument, risk-class reasoning, alternatives and unresolved facts. Pause if device status is borderline; MHRA offers a device-borderline advice channel.
Gate 2 — route and reuse memo: select valid CE recognition or UKCA for GB, separate NI analysis, record certificates and their conditions, and rank evidence gaps with accountable owners.
Gate 3 — release to execution: only after mandatory conformity and representation prerequisites are resolved, hand over validated identifiers and documents for filing; keep PMS and change-control owners assigned.

Boundary cases that overturn a quick answer

Three realistic examples show why a single “MHRA registration” quote can be the wrong first purchase:

Clinical decision app: determine whether its stated output has a medical purpose and changes clinical decisions before calling it Class I software; classification needs precise claims and functionality.
CE-marked wound product: an MDD certificate or declaration is not enough without scope, continuing validity and proof that the exact transition category is eligible.
US-made IVD sold into Belfast and London: split the NI EU/IVDR–EUDAMED path from GB MHRA registration and confirm the two representation arrangements.

Frequently asked questions

Can we register first and complete UKCA or CE evidence later?

Not as a substitute for conformity. GB MHRA registration requires the correct device status and applicable conformity documentation; registration does not legalise non-compliant devices. Resolve the route and material evidence gaps first.

Does an FDA clearance or an ISO 13485 certificate replace MHRA registration?

No. These may be useful evidence but are not, by themselves, a UK medical-device market-access route or an MHRA device registration. Assess the UK law, marking and registration separately.

Does a valid CE mark mean we need no UK Responsible Person?

No. An overseas manufacturer placing a device on the GB market ordinarily needs a UKRP even when using an eligible CE-recognition route. Northern Ireland representation is assessed under EU/NI rules.

Is an existing MDD Class I declaration enough until June 2028?

Not automatically. Certain previously self-declared products qualify only in specified upclassification or reusable-surgical-instrument situations. Verify the category, timing and conditions against MHRA guidance.

For Northern Ireland, should every device be registered on MHRA DORS?

No. Since 28 May 2026 non-custom-made devices require EUDAMED registration rather than mandatory MHRA device registration. NI custom-made devices retain the distinct MHRA registration rule within 28 days.

What does a useful consultant deliver before we pay for testing?

A signed-off intended-purpose and classification rationale, territory-by-territory route map, evidence-reuse and gap matrix, stop/go risks and named owners. No adviser can promise certification or a filing outcome from a product description alone.